Clinical Trial

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-03-26; most recent amendment 2026-01-19.
Status change: Active, Not Recruiting → Recruiting 2026-01-19
Status change: Recruiting → Active, Not Recruiting 2025-08-04
Status change: Not Yet Recruiting → Recruiting 2024-04-22
Trial Details
NCT Number NCT06333262
Lead Sponsor Inhye Ahn
Collaborators: Eli Lilly and Company
Conditions Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Enrollment 60 participants
Start Date 2024-04-22
Primary Completion 2027-07-01 (estimated)
Study Completion 2032-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-21